Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer

Author | Lynn McCain

In a manuscript published this week in JAMA Oncology, senior author Dr. Arul Chinnaiyan and members of the EDRN-PCA3 Study Group reported on their development and validation of a new 18-gene urine-based test for diagnosis of high-grade prostate cancer, MPS2. This test was initially developed in the Department of Pathology. 

Existing testing for prostate cancer results in a significant number of false positives, leading to numerous unnecessary prostate biopsies, which are invasive and painful for patients. To improve upon existing prostate cancer tests, Chinnaiyan and the EDRN-PCA3 cohort undertook a study to identify genomic  markers for high grade prostate cancers and developed a panel of 18 genes, the MPS2 test, that showed a 95% sensitivity level for Grade Group 2 prostate cancers and 99% sensitivity for Grade Group 3 prostate cancers.

Per Chinnaiyan, “This new 18-gene MPS2 test has higher diagnostic accuracy for high-grade prostate cancer relative to existing biomarker tests. Clinically, use of this test would have meaningfully reduced unnecessary biopsies performed while maintaining highly sensitive detection of high-grade cancers. These data support use of this new prostate cancer biomarker test in patients with elevated PSA levels to reduce the potential harms of prostate cancer screening while preserving its long-term benefits.” In the clinical setting, this test offers primary care physicians a straightforward pathway for their patients. A negative test rules out high-grade disease while a positive test indicates referral to a specialist. The specialist benefits from the 18-gene panel results which may guide the next step in assessment of the patient which could include imaging and/or biopsy. 

 

Citation:

Tosoian JJ, Zhang Y, Xiao L, et al. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer. JAMA Oncol. Published online April 18, 2024. doi:10.1001/jamaoncol.2024.0455

Featured News & Stories

An adult gently rests their hands on a baby who is sleeping in a NICU isolette.
Philanthropy News

A gift for Michigan’s most vulnerable babies

A gift from the Carls Foundation is helping ensure specialized care for babies and families in the Brandon NICU and Reese Partlow PCTU at C.S. Mott Children's Hospital.
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast

Barriers to Lifesaving Care for Patients with CHD

Researchers uncover barriers to recommended follow-up care for children, teens, young adults with complex congenital heart conditions.
A smiling person with short black hair and black rectangular glasses, wearing a blue blazer over a light blue button-down shirt, outdoors against a blurred background of trees.
Research News

Hanjoo Kim, Ph.D., receives $100,000 to study a new approach to depression care

Hanjoo Kim receives a $100,000 grant to develop a smartphone-based intervention that helps people with depression notice and sustain brief positive feelings.
Annual Report cover
Department News

M&I 2026 Annual Report

Read the Microbiology & Immunology Annual Report
prescription pad drawn blue yellow
Health Lab

Study reveals improving trends for treatment of opioid use disorder before surgery

Prescriptions for medications used to treat opioid use disorder increased reflecting better pain management.
Alarm clock sitting on a white dinner plate with blue and yellow flowers on the rim and a fork and knife positioned on either side of the plate.
Health Lab

Intermittent fasting can reverse diabetes in mice, study finds

Study shows intermittent fasting and meal timing can help reverse type 2 diabetes by resting pancreatic beta cells